Literature DB >> 10479172

The effect of age and natural priming on the IgG and IgA subclass responses after parenteral influenza vaccination.

A S El-Madhun1, R J Cox, L R Haaheim.   

Abstract

This study investigated the effect of natural priming and age on serum IgG and IgA subclass responses after parenteral trivalent influenza vaccination. Sera from 18 young children and 8 adults were collected at various times after vaccination. An ELISA was performed to quantify the concentrations of antibody subclasses. The children were divided into primed and unprimed groups based on the presence of prevaccination serum antibodies. In both children and adults, IgG1 and IgA1 were the predominant IgG and IgA subclasses detected after vaccination. No IgG2 responses were detected in sera of unprimed children, and the proportion of the IgG2 response was lower in primed children than in adults. This suggests that the IgG2 immune response in young children is dependent on previous priming and may mature later than the other IgG subclasses after parenteral influenza vaccination.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10479172     DOI: 10.1086/315003

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Acellular pertussis vaccines and complement killing of Bordetella pertussis.

Authors:  Alison A Weiss; Angela K Patton; Scott H Millen; Swei-Ju Chang; Joel I Ward; David I Bernstein
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

2.  Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine.

Authors:  Wilbur H Chen; Alan S Cross; Robert Edelman; Marcelo B Sztein; William C Blackwelder; Marcela F Pasetti
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

3.  Retinol binding protein and vitamin D associations with serum antibody isotypes, serum influenza virus-specific neutralizing activities and airway cytokine profiles.

Authors:  B G Jones; C M Oshansky; R Bajracharya; L Tang; Y Sun; S S Wong; R Webby; P G Thomas; J L Hurwitz
Journal:  Clin Exp Immunol       Date:  2015-11-24       Impact factor: 4.330

4.  Flexible label-free quantitative assay for antibodies to influenza virus hemagglutinins.

Authors:  Paul J Carney; Aleksandr S Lipatov; Arnold S Monto; Ruben O Donis; James Stevens
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

5.  Unusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.

Authors:  Karen K Yam; Jyotsana Gupta; Angela Brewer; David W Scheifele; Scott Halperin; Brian J Ward
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

6.  Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients.

Authors:  J Westra; S van Assen; K R Wilting; J Land; G Horst; A de Haan; M Bijl
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

Review 7.  The human antibody response to influenza A virus infection and vaccination.

Authors:  Florian Krammer
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

Review 8.  Immunological assessment of influenza vaccines and immune correlates of protection.

Authors:  Adrian Reber; Jacqueline Katz
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

9.  Effects of age on H1N1-specific serum IgG1 and IgG3 levels evaluated during the 2011-2012 influenza vaccine season.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Nicholas V Mendez; Ana Marie Landin; Bonnie B Blomberg
Journal:  Immun Ageing       Date:  2013-04-22       Impact factor: 6.400

10.  Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.

Authors:  Andrew S Herbert; Lynn Heffron; Roy Sundick; Paul C Roberts
Journal:  Virol J       Date:  2009-04-24       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.